Introduction by Professor Susan Short
In place of the annual BNOS meeting we are excited to invite you to a free one-day webinar on the theme of ‘Biomarkers in neuro oncology’. The aim of the day is to give an update on current and emerging clinically relevant biomarkers using molecular pathology, imaging and liquid biopsy approaches.
The content is aimed at clinicians, laboratory scientists and allied health care professionals.
We have excellent speakers from around the world and hope you will take advantage of our virtual meeting to engage with the experts and learn more about this important topic.
We will also be holding a free research workshop in conjunction with the Children’s Brain Tumour Drug Delivery Consortium (CBTDDC) on ‘Drug Delivery in Gliomas’ the following day, Thursday 10th September.
Timing and registration details of the online events to follow – we hope you will be able to join us!
Our high profile national and international speakers include:
Professor Cynthia Hawkins, University of Toronto; The Hospital for Sick Children
Title of talk: Pediatric gliomas: molecular features and clinical implications
Professor Cynthia Hawkins obtained her MD/PhD from Western University. She completed her residency training in neuropathology at the University of Toronto, including a post-doctoral fellowship at the University of Zurich. Professor Hawkins joined The Hospital for Sick Children (SickKids) as a neuropathologist in 2002. She is a Senior Scientist at the SickKids Research Institute and a Professor of Laboratory Medicine and Pathobiology at The University of Toronto.
Professor Hawkins’ clinical practice includes both surgical and autopsy paediatric neuropathology. She is best known for her expertise in paediatric brain tumours and has a research lab devoted to pediatric glioma. Her research interests include molecular pathogenesis and therapeutics for paediatric glioma and clinical implementation of novel diagnostic, prognostic and therapeutic markers for paediatric brain tumours. The Hawkins laboratory has contributed to the clinical, morphologic and genetic characterization of diffuse intrinsic pontine glioma (DIPG) and pediatric-type glioma as well the clinical and biologic implications of mutant histones.
Professor Norbert Galldiks, University Hospital of Cologne; Institute of Neuroscience and Medicine Germany
Title of talk: Translational PET Imaging Biomarkers
Norbert Galldiks, MD, is a Professor of Neurology, Senior Neurologist and Senior Neuro-Oncologist at the Dept. of Neurology at the University Hospital Cologne in Germany. He studied medicine at the University of Cologne and Cornell University / Memorial Sloan-Kettering Cancer Center, New York. In 2002, he qualified in medicine and received his MD from the University of Cologne, Germany. After a postdoctoral fellowship at the Max-Planck-Institute for Neurological Research in Cologne (PET laboratory) he obtained his training in Neurology at the University Hospital Cologne. Furthermore, he is Senior Research Scientist at the Institute of Neuroscience and Medicine (INM-3) at the Research Center in Juelich, Germany.
Dr. Galldiks is also Head of the Outpatient Clinic for Neuro-Oncology at the Dept. of Neurology at the University Hospital Cologne, a Board of Directors member of the Brain Tumor Center at the University Hospital Cologne, and leader of the PET Response Assessment in Neuro-Oncology Working Group (PET/RANO). He developed multiple investigator-initiated neuroimaging studies in brain tumor patients and also served in numerous national and international phase II and III clinical trials for brain tumor therapy. Additionally, he co-authored in collaboration with international major societies in the field (RANO / EANO / EANM / SNMMI) practice guidelines for PET imaging in glioma patients. Currently, he is Associate Editor for the journals Neuro-Oncology Advances and Neuro-Oncology Practice.
Dr. Galldiks has over 230 publications (Web of Science), predominantly focusing on the evaluation of gliomas and brain metastasis using PET, conventional and advanced MRI, hybrid PET/MRI, and Radiomics techniques.
Dr Farshad Nassiri, University of Toronto
Dr Gelareh Zadeh, University of Toronto
Title of joint talk: Application of plasma methylomes as liquid biopsy in brain tumours
Dr Gelareh Zadeh, MD, PhD, FRCS(C), FAANS, is a Professor of Surgery at University of Toronto, Head of the Department of Neurosurgery at Toronto Western Hospital. She is the Medical Director for the Krembil Brain Institute at Toronto Western Hospital, and Head of Surgical Oncology at University Health. Dr. Zadeh is a Senior Scientist at Princess Margaret Cancer Centre where she runs a translational research program at MacFeeters-Hamilton Neuro-oncology Program. She is also a Chair for the Wilkins Family Brain Tumor Research.
Dr. Zadeh has a dedicated neuro-oncology and skull base practice, which include a number of multidisciplinary specialized programs including a skull base clinic, brain metastases, pituitary clinic, and neurofibromatosis clinics. In parallel, she has an active research laboratory focusing on integrated multi-platform molecular analysis of brain tumors, together with a focus on understanding molecular response to targeted therapies, such as anti-angiogenesis and metabolic inhibitors. She is also involved in a number of national and international organizations, she is President of Society of Neuro-Oncology (SNO), and the Chair of Neuro-oncology Committee at the World Federation of Neurological Surgeons, she is the Co-Chair and founder of the consortium on meningiomas, in collaboration with Society of Neuro-Oncology.
Dr Farshad Nassiri is a senior neurosurgery resident in the Division of Neurosurgery at the University of Toronto. He is completing his PhD concurrent to his clinical training at the University of Toronto, where his work focuses on elucidating biomarkers of clinical outcome for brain tumors. He is the recipient of the prestigious Vanier Scholar award for the Canadian Institute for Health Research, and is a Fellow of the Neurosurgery Research & Education Foundation from the American Association for Neurological Surgeons as well as a Fellow of the Hold’em for Life Oncology chapter.
Dr. Nina Struve, University of Hamburg-Eppendorf
Title of talk: New insights into EGFR and EGFRvIII as a biomarker in GBM
Nina is a postdoctoral fellow working in the Lab of Radiobiology & experimental Radiooncology at the University Medical Center Hamburg-Eppendorf (Germany). Her research focuses on Glioblastoma Multiforme (GBM), which is an aggressive primary brain tumor, characterized by rapid progression and oncogene activation. One common and frequently expressed oncogene in GBM is the constitutively activated epidermal growth factor receptor deletion mutant EGFRvIII. EGFRvIII represents a typical oncoprotein that activates different signaling pathways altering thereby multiple cellular processes. Therefore, understanding how EGFRvIII impacts therapy relevant processes like DNA repair, replication and cellular signaling are her main research interest.
We would like to extend a warm thank you to all our online day sponsors
Updated: July 2020